Table 2 Patient characteristics.
Men with an elevated PSA not undergoing subsequent biopsy N = 259 | Men who received a biopsy N = 370 | ||||
|---|---|---|---|---|---|
Complete marker and DRE data N = 262 | Missing marker or DRE N = 108 | ||||
No Cancer N = 179 | Cancer N = 83 | No Cancer N = 76 | Cancer N = 32 | ||
Age at screening (years) | 64 (59, 67) | 63 (59, 67) | 65 (61, 69) | 65 (60, 67) | 65 (61, 68) |
Total PSA | 3.75 (3.12, 4.80) N = 228 | 4.23 (3.36, 5.58) | 4.86 (3.81, 7.23) | - | - |
Free PSA | 0.88 (0.67, 1.15) N = 228 | 1.01 (0.77, 1.32) | 0.96 (0.67, 1.36) | - | - |
Intact PSA | 0.38 (0.27, 0.56) N = 228 | 0.45 (0.34, 0.63) | 0.50 (0.33, 0.75) | - | - |
Human Kallikrein 2 | 0.061 (0.038, 0.094) N = 216 | 0.061 (0.036, 0.090) | 0.088 (0.050, 0.132) | - | - |
Number of biopsy cores | - | 12 (10, 12) | 12 (10, 12) | 11 (6, 12) | 10 (6, 12) |
Clinical T Stage | |||||
T1 | - | - | 31 (37%) | - | 13 (41%) |
T2 | - | - | 39 (47%) | - | 12 (38%) |
T3 | - | - | 8 (10%) | - | 1 (3%) |
Missing | - | - | 5 (6%) | - | 6 (19%) |
Biopsy Gleason Grade | |||||
<= 6 | - | - | 33 (40%) | - | 17 (53%) |
7 | - | - | 33 (40%) | - | 11 (34%) |
>= 8 | - | - | 12 (14%) | - | 3 (9%) |
Missing | - | - | 5 (6%) | - | 1 (3%) |